Friday, June 16, 2017
The need for an alternative to the paper-based clinical trial process is long overdue. Not only is the original method cost- and labor-intensive, but it can delay new drug development, as well. The first siteless technology model for clinical trial research was introduced last year, and since then studies in this area continue.
Laboratory Corporation of America (LabCorp) has announced that Covance Drug Development has been awarded the 2016 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award. Covance has received this significant recognition for three consecutive years for its continuing efforts to expand the scope of drug development services it provides in the growing Asia Pacific region.
Cytori Therapeutics has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of regenerative medicine for over a decade. Frost & Sullivan’s industry research and benchmarking analysis report that Cytori’s pioneering technology platform has become the leading technology to enable the research and practice of cellular therapies that harness the potential of stem and regenerative cells from adipose tissue.
Due to newly commercialized solutions and pent up demand, wearables dedicated to chronic disease monitoring and other clinical applications are expected to transform care provision models.
Chris Edwards, CMO at Validic, provider of digital health platform, has won the 2015 CMO Growth Award from The CMO Club.
WuXi PharmaTech, a Shanghai-based open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, has received the 2015 Asian CRO Company of the Year award from Frost & Sullivan, a business research and consulting firm.